Vancouver, British Columbia, September 29, 2022 /PR Newswire/ – Asep Medical Holdings Co., Ltd. (hereafter, Asep Co., Ltd.) or “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of a PhD. Richard Heinzl Effective immediately on the Board of Directors of the Company.

Dr. Richard Heinzl Joins Board of Asep Inc. (CNW Group/ASEP Medical Holdings Inc.)

Dr. Richard Heinzl Joins Board of Asep Inc. (CNW Group/ASEP Medical Holdings Inc.)

Dr. Heinzl is a physician, humanitarian, entrepreneur, and author with a current focus on genomics, artificial intelligence, and healthcare worldwide.original New York When Torontohe is currently CEO of My Next Health Inc., a next-generation functional genomics company.

Early in his career, Dr. Heinzl was the founder of the Canadian chapter of Doctors Without Borders/Doctors Without Borders (MSF Canada), winner of the Nobel Peace Prize in 1999. bostonbased on, harvard– Affiliated virtual medical companies.he graduated of McMaster University Michael G. DeGroot School He holds a doctorate in medicine and a postgraduate degree related to global health. Harvard University and the oxford universityhe is an honorary fellow American College of Preventive MedicineHis work and travels have taken him to over 80 countries. North America and abroad. He was awarded an Honorary Doctorate (LLD) from his alma mater in 2000. McMaster University Named one of the 100 People Who Make a Difference. Canada From Penguin Books.of September 2016Harvard TH Chan School of Public Health Alumni Award of Merit, the school’s highest award.

Dr. Heinzl said: Bob Hancock Visionary scientific leadership. It is really exciting that biotechnology has great potential to change the paradigm of human healthcare. ”

“Having world-class physicians and entrepreneurs on our board strengthens our mission to address unmet medical needs in the large unmet market associated with antibiotic failures. will support you. Robert Hancock, CEO and co-founder of Asep. “Richard provides the Board with a strong medical and global perspective.”


Asep Medical Inc. ( is dedicated to addressing antibiotic failure by developing new solutions for critical unmet medical needs. The Company is a merger of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.), both of which are highly developed proprietary diagnostic tools for early and early detection of severe sepsis and broad-spectrum treatment. Allows for timely identification. A drug to combat multidrug-resistant biofilm infections.

Sepset Biosciences Inc. ( has developed a patient gene expression signature that is predictive of severe sepsis, one of the critical illnesses leading to antibiotic failure, as antibiotics are the main treatment for sepsis. We are developing diagnostic techniques including: Nevertheless, sepsis is responsible for nearly 20% of all deaths on earth.Sepsetendoplasmic reticulum The test is an easy-to-implement, blood-based gene expression assay that provides results in approximately one hour in the emergency room or intensive care unit. This unique diagnostic technology differs from current diagnostic tests that allow diagnosis of severe sepsis within 1-2 hours of first clinical presentation (i.e., emergency room), whereas other diagnoses can be made within 24-24 hours. Only provides a diagnosis after 36 hours. Asep Inc. believes this will enable physicians to make important early decisions regarding appropriate treatment and reduce overall morbidity and mortality from sepsis.

ABT Innovations Inc. (’s peptide technology is used for a wide range of diseases including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wounds, dental, skin, ENT, sinusitis). It covers therapeutic applications. , orthopedics, etc.), anti-inflammatory agents, anti-infective immunomodulators, and vaccine adjuvants.

Forward-Looking Statements —

This news release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements “anticipate,” “plan,” “continue,” “expect,” “predict,” “intend,” “believe,” “project,” “estimate.” , is often characterized by words such as “may”. , “would,” “may,” “proposed,” “placed,” and other similar words, or that a particular event or condition “could occur” or “occur.” Description. These statements include, but are not limited to, successful clinical trials and filings for regulatory approval of our sepsis diagnostic test. It is hoped that this will lead to rapid clinical trials. Throughout this news release, various assumptions have been used in forming the conclusions or projections contained in the forward-looking statements. Forward-looking statements are based on management’s opinions and assumptions at the time the statements were made and are subject to various risks, including risk factors identified in Asep Medical Inc.’s prospectus. ). November 9, 2021) uncertainties and other factors, which can be found in the company profile on, that could cause actual events or results to differ materially from those projected by the forward-looking statements.Asep Medical Inc. does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law, nor does it intend or oblige to do so. expressly disavows.

Asep Medical Holdings Inc. (CNW Group/ASEP Medical Holdings Inc.)

Asep Medical Holdings Inc. (CNW Group/ASEP Medical Holdings Inc.)



View original content and download multimedia: board-of-directors-301637346.html

Source: ASEP Medical Holdings Co., Ltd.

Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *